Skip to main content


The UNC Blood Research Center (BRC) was established to promote interdisciplinary research in non-malignant blood disorders across UNC. It will seek to advance the work in the following specific areas.



One in four of the US population will succumb to a terminal thrombotic event, such as: myocardial infarction, stroke, or venous thromboembolism.

Basic science discoveries have paved the way towards better prophylactic and therapeutic approaches to thrombosis. However, a better understanding of the mechanisms underlying thrombosis and prevention without any risk of bleeding remains an unmet need. The BRC seeks to investigate potential approaches to both aims.

Bleeding Disorders

UNC is a world leader in hemophilia, from the development and administration of the first coagulation factor VIII concentrate to the role of the Chapel Hill dog colonies of the Francis Owen Blood Research Center in the pre-clinical testing of protein and gene therapies. The BRC aims to address the broad challenges that remain in numerous other inherited and acquired bleeding disorders.

Sickle Cell Disease

Sickle cell disease affects approximately 100,000 Americans but accounts for an estimated 300,000 births worldwide every year, primarily in sub-Saharan Africa and the Indian sub-continent.

Compared to many other areas of medicine, the development of impactful therapies in sickle cell disease remains inadequate. We will continue to expand our research efforts to this under-served patient population into the future.



Recent Posts

News from the Blood Research Center

More posts

2 weeks ago

Lancet Haematology Journal Commentary: Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark

We might never know the answer to these specific questions, but we should continue to document realworld findings, particularly regarding the risks and benefits of voxelotor to end-organ function. Building on preclinical models,7 preliminary studies showing preserved or lowered cerebral blood flow,8 together with the results of this study1 and ongoing studies, such as HOPE …

1 month ago

Publication news! Plasmin-mediated Cleavage of High Molecular Weight Kininogen Contributes to Acetaminophen-Induced Acute Liver Failure

Michael Henderson, PhD, Key lab of the Blood Research Center has first author publication: Abstract Acetaminophen (APAP)-induced liver injury is associated with activation of coagulation and fibrinolysis. In mice, both tissue factor-dependent thrombin generation and plasmin activity have been shown to promote liver injury after APAP overdose. However, the contribution of the contact and intrinsic …